Recent Updates
Recently added Catalysts
ALVO Negative Sentiment Score: 25/100

ALVOTECH ALERT: Bragar Eagel & Squire, P.C. is Investigating Alvotech on Behalf of Alvotech Stockholders and Encourages Investors to Contact the Firm

Key Takeaway: Bragar Eagel & Squire, P.C. is investigating Alvotech on behalf of its stockholders for potential violations of federal securities laws. This investigation comes after Alvotech received a complete response letter from the FDA regarding its biosimilar candidate AVT02 for Humira, highlighting deficiencies that need to be addressed. Following this announcement, Alvotech's stock experienced a significant decline. The law firm is encouraging affected investors to reach out for more information about their rights and any potential claims.

Market Sentiment Analysis

CONCERNS & RISKS

  • Alvotech is under investigation for potential claims regarding violations of federal securities laws.
  • The company received a complete response letter from the FDA, indicating significant deficiencies that must be resolved before approval.
  • Alvotech's stock price fell sharply following the negative news from the FDA.

Full Press Release Details

NEW YORK, May 03, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Alvotech (“Alvotech” or the “Company”) (NASDAQ: ALVO) on behalf of Alvotech stockholders. Our investigation concerns whether Alvotech has violated the federal securities laws and/or engaged in other unlawful business practices.
Click here to participate in the action.
On April 13, 2023, Alvotech issued a press release "announc[ing]…that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for Alvotech's Biologics License Application (BLA) for AVT02, a high-concentration biosimilar candidate for Humira® (adalimumab). The CRL noted that certain deficiencies, which were conveyed following the FDA's reinspection of the company's Reykjavik facility that concluded on March 17, 2023, must be satisfactorily resolved before the application can be approved."
On this news, Alvotech's stock price fell sharply during intraday trading on April 14, 2023.
If you purchased or otherwise acquired Alvotech shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form.  There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.

Tags

Frequently Asked Questions

What is the investigation about Alvotech?

Bragar Eagel & Squire, P.C. is investigating potential claims against Alvotech regarding possible violations of federal securities laws.

What triggered the drop in Alvotech's stock price?

Alvotech's stock price fell sharply after the FDA issued a complete response letter for AVT02.

Who can participate in the Alvotech investigation?

Individuals who purchased Alvotech shares, experienced losses, or have relevant information can participate.

How can I contact the law firm for more information?

You can reach out via email at investigations@bespc.com or by calling (212) 355-4648.

What does Bragar Eagel & Squire, P.C. specialize in?

The firm specializes in representing investors in commercial and securities litigation across the U.S.

Last updated: May 4, 2023